Alza/McNeil Concerta
Executive Summary
"Approvable" letter received May 18 for once-daily OROS formulation of methylphenidate for ADD/ADHD. FDA is not requesting additional clinical data, and the companies continue to plan for a fall launch (1"The Pink Sheet" April 24, p. 7). The NDA was submitted July 21, 1999
You may also be interested in...
Alza/McNeil Concerta 420-Rep Sales Force Will Target Peak October Season
Alza and McNeil Consumer Healthcare are preparing a combined sales force of 420 reps to detail Alza's once-daily methylphenidate treatment Concerta for pediatric attention deficit/hyperactivity disorder.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials